MURSLA
Mursla is a breakthrough exosome characterisation company based on a novel proprietary technology platform, ExoPheno™, which detects the multi-omics cargo of tissue-specific exosomes in blood for various biomedical applications. Exosomes (also known as Extracellular Vesicles) have been shown to reflect the state of their cellular sources, transporting specific ‘-omics’ information (DNA, RNA, proteins, lipids and metabolites) either locally or to distant sites via the circulatory system, including blood.
MURSLA
Industry:
Biotechnology Health Diagnostics Information Technology Internet Of Things Medical Device
Founded:
2019-03-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.mursla.com
Total Employee:
11+
Status:
Active
Total Funding:
750 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Organization Schema Google Apps For Business Google Maps Person Schema Google
Current Employees Featured
Tomas Dias CTO @ Mursla
CTO
2021-06-01
Pierre Arsène Founder and CEO @ Mursla
Founder and CEO
2017-09-01
Founder
Investors List
Greater London Authority
Greater London Authority investment in Grant - Mursla
Official Site Inspections
http://www.mursla.com Semrush global rank: 3.6 M Semrush visits lastest month: 3.99 K
- Host name: 80.26.180.107.host.secureserver.net
- IP address: 107.180.26.80
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Mursla"
Mursla Bio | Pioneering dynamic biopsy
Mursla Bio's transformative biopsy platform is non-invasive and provides a dynamic view of the biological processes within a specific organ or tissue. This approach combines the high …See details»
About - Mursla Bio
The 21st century will be marked by the convergence of artificial intelligence, fuelled by Moore's Law ('Mursla' pronounced in Japanese), and the increasing ability to decode the complex language of biology ('Bio')See details»
Mursla Bio - Crunchbase Company Profile & Funding
Mursla Bio is a pioneering biotech company on a mission to transform cancer care by pushing the boundaries of biopsy technology. Its breakthrough dynamic biopsy platform combines the strengths of both tissue and liquid biopsies …See details»
Mursla Bio Company Profile 2024: Valuation, Funding & Investors
Operator of a liquid biopsy company focused on decoding extracellular vesicles to enable curative treatments.See details»
Mursla Bio - LinkedIn
Mursla Bio is a pioneering biotech company on a mission to transform cancer care by pushing the boundaries of biopsy technology. Its breakthrough dynamic biopsy platform combines the strengths...See details»
Pierre Arsène - Founder & CEO at Mursla - The Org
Finally, in 2017, they became the Founder & CEO of Mursla, a multi-omics exosome characterisation company based in Cambridge. Pierre's current work focuses on second …See details»
Mursla - Products, Competitors, Financials, Employees, …
Mursla is a biotechnology company focused on developing non-invasive diagnostic tests for liver cancer. The company's main product is an AI-assisted In Vitro Diagnostic (IVD) blood test that …See details»
Member profile: Mursla Bio | BIA - bioindustry.org
Mursla Bio is a breakthrough extracellular vesicle characterisation company based on a novel proprietary technology platform, ExoPheno™, which detects the multi-omics cargo of tissue …See details»
Mursla Bio’s EvoLiver surpasses current standards in liver cancer ...
Nov 18, 2024 · Mursla Bio developed the EvoLiver test by isolating organ-specific hepatocyte extracellular vesicles (h-EVs) from blood samples, enabling the validation of a novel HCC …See details»
Pierre Arsène - Founder and CEO @ Mursla Bio - Crunchbase
Pierre is a biotech entrepreneur and is the Founder and CEO of Mursla Bio, a company decoding cellular messengers to enable curative treatments for cancer. He conducted postgraduate …See details»
Mursla | VentureRadar
Mursla is developing a breakthrough technology for early cancer detection using liquid biopsies; offering a less invasive and more responsive approach to diagnosis; treatment and cure. The …See details»
Mursla Bio - BIO International Convention | BIO
Jun 7, 2023 · - Mursla (Cambridge, UK) is an emergent techbio startup, leveraging extracellular vesicle biology to deliver nextgen multi-omics liquid biopsy tests. - Its first product is a blood …See details»
Mursla Bio joins leading European consortium to advance clinical ...
Nov 12, 2024 · Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy …See details»
Mursla Bio joins leading European consortium to advance clinical ...
Nov 12, 2024 · Mursla Bio will provide oversight on the work package ‘scaling and commercialization’ of EV products, especially for clinical diagnostics. Additionally, Mursla Bio …See details»
Mursla Bio Presents Breakthrough Liquid Biopsy Technology for ...
Jun 3, 2024 · Mursla Bio is a liquid biopsy company decoding extracellular vesicles to enable curative treatments for cancer. Its first-in-class blood test is based on a novel modality, …See details»
Mursla Bio enters the US market with strategic expansion
Mursla Bio is a liquid biopsy company pioneering a novel technology that analyses intercellular messengers (“extracellular vesicles”) to better diagnose cancer. Its first-in-class blood testing …See details»
Mursla Unveils Novel Bead-Nanochip Technology for …
Apr 13, 2022 · Key features of the technology include: Ultrasensitive detection of target exosomes and their markers. Compatibility with clinical practices in a high throughput format. …See details»
Mursla - VentureRadar
Mar 8, 2018 · Website: http://mursla.com. Mursla is developing a breakthrough technology for early cancer detection using liquid biopsies; offering a less invasive and more responsive …See details»
News - Mursla Bio
Mursla Bio was selected to support scaling and commercialization strategy for extracellular vesicle-based disease surveillance and diagnostics … Mursla Bio launches US strategy to …See details»
Science and Technology - Mursla Bio
Mursla Bio pioneered three EV technologies to achieve optimal clinical outcomes: (i) Organ-specific EV isolation, (ii) AI-enabled multi-omics biomarker discovery from EV cargo, (iii) …See details»